Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 2/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 7/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22843545 | 0.81 | CDK1 (0.54) | NT5EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL22843642 | 0.79 | CDK1 (0.56) | NT5E | |
| SCHEMBL22843632 | 0.78 | NT5E (0.54) | NT5EMAPK1 | |
| SCHEMBL22843693 | 0.77 | NT5E (0.55) | NT5EMAPK1 | |
| SCHEMBL22843638 | 0.77 | NT5E (0.55) | NT5EMAPK1 | |
| SCHEMBL22843495 | 0.77 | CDK2 (0.49) | NT5ERAB9A | |
| SCHEMBL22843544 | 0.77 | NT5E (0.55) | NT5EMAPK1 | |
| SCHEMBL22843617 | 0.77 | KDM4E (0.46) | NT5EMAPK1 | |
| SCHEMBL22843701 | 0.77 | CDK1 (0.46) | NT5E | |
| SCHEMBL22843654 | 0.77 | CDK1 (0.52) | NT5EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | PDE1A 693/4885PDE1B 735/4885PDE1C 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.